Search | Page 6 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. A Rare Case of Aplastic Anemia Later in Life Doesn’t Stop Al Meyer

    ... had no response to.  So in late 2013, they put me in a clinical trial for eltrombopag, which I had already tried once before, but this is ...

    Patient Chronicle last updated 07/12/2017 - 1:52pm.

  2. Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes.

    ... hematopoietic responses were observed in a recent clinical trial using eltrombopag in patients with severe aplastic anemia refractory ...

    Research Article last updated 06/20/2013 - 10:13am.

  3. Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS

    ... 4, 2014 Reliable clinical or molecular predictors of benefit from azacitidine therapy ... whose data was collected in a prospective clinical trial with a longer median follow-up. We found a significant association ...

    Research Article last updated 08/04/2014 - 8:37am.

  4. 5-Azacytidine in myelodysplastic syndromes: a clinical practice guideline.

    ... the treatment or management of MDS. Of those, six clinical articles of prospective phase 2-3 study design or meta-analyses were ... agents at this time outside the context of a clinical trial . Bone Marrow Diseases:  ...

    Research Article last updated 10/11/2011 - 5:58pm.

  5. Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia

    ... with >30% blasts have also been shown in a recent phase III trial. Oral administration of azacitidine may enhance patient convenience, ... oral azacitidine (CC-486) have shown biological activity, clinical responses, and tolerability in patients with MDS and AML. Extended ...

    Research Article last updated 12/09/2015 - 8:49am.

  6. CASCADE (SGN33A-005)

    For more details on this clinical trial, including contact information, please see this trial’s listing on ... the efficacy, appropriateness or suitability of any clinical trial listed on this website. Pharmaceutical company sponsored ...

    Clinical Trial last updated 06/19/2017 - 2:43pm.

  7. Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS

    For more details on this clinical trial, including contact information, please see this trial’s listing on ... the efficacy, appropriateness or suitability of any clinical trial listed on this website. Pharmaceutical company sponsored ...

    Clinical Trial last updated 06/19/2017 - 2:44pm.

  8. p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)

    ... treated with lenalidomide in the MDS-004 clinical trial were retrospectively assessed for p53 expression by ... syndromes. This study is based on data from the MDS 004 trial (clinicaltrials.gov identifier: NCT00179621). ...

    Research Article last updated 04/23/2014 - 12:26pm.

  9. Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment.

    ... changing MDS environment is raising new challenges in clinical trial design and defining new indications for MDS drugs. Many current ...

    Research Article last updated 10/11/2011 - 5:58pm.

  10. Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations.

    ... is expanding rapidly, but limited comparative clinical trial data are available to (i) define the optimal use of azacitidine in ...

    Research Article last updated 07/09/2013 - 3:03pm.